Substantial Expansion in Cannabis Operations and Grow Facilities in North America Leading to Increased Production and Revenues

Tuesday, June 20, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

PALM BEACH, Florida, June 20, 2017 /PRNewswire/ --

In today's

legal marijuana developments around the burgeoning cannabis sector across North America, industry leaders are ramping up production levels and racing to introduce the newest and higher quality products and services. The
acquisition and development of commercial space for expanded grow facilities alone is continuing to drive potential revenues to new heights. Cannabis companies in the news and market activity to watch today include: MYM Nutraceuticals Inc. (OTC: MYMMF) (CSE: MYM.CN), Cannabics Pharmaceuticals Inc. (OTC: CNBX), Aurora Cannabis Inc. (TSX-V: ACB.V) (OTC: ACBFF), Canopy Growth Corporation (TSX: WEED.TO) (OTC: TWMJF) and InMed Pharmaceuticals Inc. (CSE: IN.CN) (OTC: IMLFF).

MYM Nutraceuticals Inc. (OTCQB: MYMMF) (CSE: MYM.CN) is extremely pleased to announce that it has signed an exclusive deal with the Municipality of Weedon, Québec ('Weedon') to build a 1.5 million-square-foot cannabis production facility consisting of fifteen 100,000-square-foot greenhouses. Once the entire project is completed and licensed, it would be one of the largest grow operations in the world, with the potential to produce over 150,000 kilograms of cannabis per year or $750,000,000 annually. This is a first of its kind partnership where a municipality has partnered with a cannabis company to build a major production facility. The agreement is unique as Weedon will purchase the 329 acres of land for MYM to build the project on. Read this and more news for MYM Nutraceuticals at

The Weedon agreement was signed by a subsidiary of MYM, CannaCanada Inc., a Montréal-based cannabis company that MYM purchased 75% of. By the completion of the project, MYM will own 90% of CannaCanada Inc. CannaCanada's strong ties with Weedon city officials allowed MYM to also obtain full exclusivity regarding the future development of any cannabis or hemp-growing facilities within the municipality. The municipality of Weedon, which is approximately two hours east of Montréal, is actively involved in the project. Weedon has already identified the land on which the facility will be built and has signed an option to purchase it. Subject to certain requirements, Weedon will exercise that option and then donate the land to the project. 

MYM anticipates that the project will advance quickly as Weedon's planning department has already approved the preliminary construction designs for the initial portion of the facility. Detailed plans for the first 100,000-sq-ft greenhouse and a 20,000-sq-ft warehouse are now being drawn up by the MYM's architects, Latimer Hu. MYM has engaged Factotum Consultants, who have successfully obtained two Licensed Producer licenses for other clients, to manage the ACMPR application process and expects to submit its application to Health Canada this Friday.

In other Cannabis industry developments and market activity of note:  

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) had a strong open to the week, closing up 11% on over 1.8 million shares traded on Monday. Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

Aurora Cannabis Inc. (OTCQX: ACBFF) (TSX-V: ACB.V) - ACBFF closed up 3.04% on Monday on the OTC Markets after trading north of 290,000 shares by the market close. ACB.V closed up over 2% at $2.16 on the TSX exchange on Monday as well trading over 1.3 Million shares. Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ('ACMPR'). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , and is currently constructing a second 800,000 square foot production facility, known as 'Aurora Sky', at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec , on Montreal's West Island. Aurora also recently acquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ('EU'), based in Berlin, Germany.

Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO) - TWMJF finished Monday up 2.03% on the OTC Markets with over 220,000 shares traded, while WEED.TO closed up at $7.95 trading over 880,000 shares by the market close. Canopy Growth Corporation, through its subsidiaries, produces and sells medical marijuana in Canada. The company offers dry cannabis and oil products primarily under the Tweed and Bedrocan brands. It also sells its products through online. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. The company is headquartered in Smiths Falls, Canada.

InMed Pharmaceuticals Inc. (OTCQB: IMLFF) (CSE: IN.CN) - IMLFF closed Monday up 1.80% on the OTC markets with over 350,000 shares traded. On the CSE Canadian exchange, IN.CN closed down very slightly at $0.37 on Monday. InMed recently shared the progress of advancing its lead clinical trial candidate. InMed Pharma is a pre-clinical stage biopharmaceutical company that specializes in the development of cannabinoid-based prescription drug therapies that leverage its novel drug delivery systems. Using a proprietary bioinformatics database, the company rapidly identifies cannabinoid compounds with the potential to address serious medical conditions. This process enables the company to efficiently develop highly-specialized therapies across many conditions. Read the full release here:

DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated five thousand nine hundred dollars for news coverage of the current press release issued by MYM Nutraceuticals Inc., by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Media Contact E-mail: Phone: +1(561)325-8757


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store